Dietary advanced glycation end products are associated with decline in memory in young elderly

Mechanisms of Ageing and Development

Volumn 140, Issue 1, 2014, Pages 10-12

  West, Rebecca K ^a   Moshier, Erin ^a   Lubitz, Irit ^b   Schmeidler, James ^a   Godbold, James ^a   Cai, Weijing ^a   Uribarri, Jaime ^a   Vlassara, Helen ^a   Silverman, Jeremy M ^a,c   Beeri, Michal Schnaider ^a,b  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b SHEBA MEDICAL CENTER   (Israel)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Cognitive decline; Dietary advanced glycation end products; Memory; Methylglyoxal; Type 2 diabetes

Indexed keywords

ADVANCED GLYCATION END PRODUCT; METHYLGLYOXAL;

AGED; ARTICLE; ATTENTION; CARDIOVASCULAR RISK; COGNITION; DEMOGRAPHY; DIET; EXECUTIVE FUNCTION; FEMALE; FOLLOW UP; HUMAN; HUMAN EXPERIMENT; LANGUAGE; MALE; MEMORY; MINI MENTAL STATE EXAMINATION; NEUROPSYCHOLOGY; NORMAL HUMAN; PRIORITY JOURNAL; SOCIAL ASPECT; ADVERSE EFFECTS; BLOOD; COGNITION DISORDERS; MEMORY DISORDERS; MIDDLE AGED; REGRESSION ANALYSIS;

AGED; COGNITION DISORDERS; DIET; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; MALE; MEMORY DISORDERS; MIDDLE AGED; PYRUVALDEHYDE; REGRESSION ANALYSIS;

EID: 84905220058     PISSN: 00476374     EISSN: 18726216     Source Type: Journal    
DOI: 10.1016/j.mad.2014.07.001     Document Type: Article

References (17)

1. Beeri M.S., Moshier E., Schmeidler J., Godbold J., Uribarri J., Reddy S., Sano M., Grossman H.T., Cai W., Vlassara H., Silverman J.M. Serum concentration of an inflammatory glycotoxin, methylglyoxal, is associated with increased cognitive decline in elderly individuals. Mech. Ageing Dev. 2011, 132:583-587.
2. Cai W., Uribarri J., Zhu L., Chen X., Swamy S., Zhao Z., Grosjean F., Simonaro C., Kuchel G.A., Schnaider-Beeri M., Woodward M., Striker G.E., Vlassara H. Oral glycotoxins are a modifiable cause of dementia and the metabolic syndrome in mice and humans. PNAS 2012, 111:4940-4945.
3. Goh S.Y., Cooper M.E. The role of advanced glycation end products in progression and complications of diabetes. J. Clin. Endocrinol. Metab. 2008, 93:1143-1152.
4. Krautwald M., Münch G. Advanced glycation end products as biomarkers and gerontotoxins - a basis to explore methylglyoxal-lowering agents for Alzheimer's disease?. Exp. Gerontol. 2010, 45:744-751.
5. Li J., Liu D., Sun L., Lu Y., Zhang Z. Advanced glycation end products and neurodegenerative diseases: mechanisms and perspective. J. Neurol. Sci. 2012, 317:1-5.
6. Li X.H., Du L.L., Cheng X.S., Jiang X., Zhang Y., Lv B.L., Liu R., Wang J.Z., Zhou X.S. Glycation exacerbates the neuronal toxicity of β-amyloid. Cell Death Dis. 2013, 4:e673.
7. Lim Y.Y., Maruff P., Piertrzak R.H., Ellis K.A., Darby D., Ames D., Harrington K., Martins R.N., Masters C.L., Szoeke C., Savage G., Villemagne V.L., Rowe C.C. Aβ and cognitive change: examining the preclinical and prodromal stages of Alzheimer's disease. Alzheimers Dement. 2014, (Epub ahead of print).
8. McCrimmon R.J., Ryan C.M., Frier B.M. Diabetes and cognitive dysfunction. Lancet 2012, 379:2291-2299.
9. McGuinness B., Barrett S.L., Craig D., Lawson J., Passmore A.P. Attention deficits in Alzheimer's disease and vascular dementia. J. Neurol. Neurosurg. Psychiatry 2010, 81:157-159.
10. Ramos-Fernández E., Tajes M., Palomer E., Ill-Raga G., Bosch-Morató M., Guivernau B., Román-Dégano I., Eraso-Pichot A., Alcolea D., Fortea J., Nuñez L., Paez A., Alameda F., Fernández-Busquets X., Lleó A., Elosúa R., Boada M., Valverde M.A., Muñoz F.J. Posttranslational nitro-glycative modifications of albumin in Alzheimer's disease: implications in cytotoxicity and amyloid-β peptide aggregation. J. Alzheimers Dis. 2014, Epub ahead of print.
11. Segura B., Jurado M.A., Freixenet N., Albuin C., Muniesa J., Junque C. Mental slowness and executive dysfunctions in patients with metabolic syndrome. Neurosci. Lett. 2009, 462:49-53.
12. Srikanth V., Westcott B., Forbes J., Phan T.G., Beare R., Venn A., Pearson S., Greenaway T., Parameswaran V., Munch G. Methylglyoxal, cognitive function and cerebral atrophy in older people. J. Gerontol. A: Biol. Sci. Med. Sci. 2013, 68:68-73.
13. Southern L., Williams J., Esiri M.M. Immunohistochemical study of N-epsilon-carboxymethyl lysine (CML) in human brain: relation to vascular dementia. BMC Neurol. 2007, 7:35-42.
14. Uribarri J., Woodruff S., Goodman S., Cai W., Chen X., Pyzik R., Yong A., Striker G.E., Vlassara H. Advanced glycation end products in food and a practical guide to their reduction in the diet. J. Am. Diet. Assoc. 2010, 110:911-916.
15. Vlassara H., Cai W., Goodman S., Pyzik R., Yong A., Chen X., Zhu L., Neade T., Beeri M., Silverman J.M., Ferruci L., Tansman L., Striker G.E., Uribarri J. Protection against loss of innate defenses in adulthood by low advanced glycation end products (AGE) intake: role of the antiinflammatory AGE receptor-1. J. Clin. Endocrinol. Metab. 2009, 94:4483-4491.
16. Wiederkehr S., Laurin D., Simard M., Verrault R., Lindsay J. Vascular risk factors and cognitive functions in nondemented elderly individuals. J. Geriatr. Psychiatry 2009, 22:196-206.
17. Yaffe K., Lindquist K., Schwartz A.V., Vitartis C., Vittinghoff E., Satterfield S., Simonsick E.M., Launer L., Rosano C., Cauley J.A., Harris T. Advanced glycation end product level, diabetes, and accelerated cognitive aging. Neurology 2011, 77:1351-1356.